Facile synthesis of new carbon-11 labeled conformationally restricted rivastigmine analogues as potential PET agents for imaging AChE and BChE enzymes

Min Wang, Ji Quan Wang, Mingzhang Gao, Qi Huang Zheng

Research output: Contribution to journalArticle

4 Scopus citations


Rivastigmine is a newer-generation inhibitor with a dual inhibitory action on both acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) enzymes, and is used for the treatment of AChE- and BChE-related diseases such as brain Alzheimer's disease and cardiovascular disease. New carbon-11 labeled conformationally restricted rivastigmine analogues radiolabeled quaternary ammonium triflate salts, (3aR,9bS)-1-[11C]methyl-1-methyl-6-(methylcarbamoyloxy)-2,3,3a,4,5,9b-hexahydro-1H-benzo[g]indolium triflate ([11C]8) and (3aR,9bS)-1-[11C]methyl-1-methyl-6-(heptylcarbamoyloxy)-2,3,3a,4,5,9b-hexahydro-1H-benzo[g]indolium triflate ([11C]9), were designed and synthesized as potential positron emission tomography (PET) agents for imaging AChE and BChE enzymes. The appropriate precursors were labeled with [11C]CH3OTf through N-[11C]methylation, and the target tracers were isolated by solid-phase extraction (SPE) using a cation-exchange CM Sep-Pak cartridge in 40-50% radiochemical yields decay corrected to end of bombardment (EOB), 15-20 min overall synthesis time, and 148-222 GBq/μmol specific activity at EOB.

Original languageEnglish (US)
Pages (from-to)506-512
Number of pages7
JournalApplied Radiation and Isotopes
Issue number4
StatePublished - Apr 1 2008



  • Acetylcholinesterase (AChE)
  • Butyrylcholinesterase (BChE)
  • Carbon-11
  • Conformationally restricted analogues
  • Imaging
  • Positron emission tomography (PET)
  • Rivastigmine

ASJC Scopus subject areas

  • Radiation

Cite this